Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2044

Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.

Patents
1,766

Quick answer

1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12123036

    Soluble ACE2 variants and uses therefor

    Northwestern University · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12121524

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2024219427

    PROCÉDÉ DE PRODUCTION DE LYMPHOCYTES INNÉS DE TYPE 2

    UNIV KYOTO [JP] · Granted Thu Oct 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12128034

    Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof

    Iterum Therapeutics International Limited · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12128092

    Lyophilized factor IX formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12128109

    Muscle targeting complexes and formulations for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12128122

    Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic

    Krystal Biotech, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12128102

    Constrained conditionally activated binding proteins

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12128133

    Ingestible device with expandable enclosure

    Rani Therapeutics, LLC · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12129263

    Kinase inhibitors and uses thereof

    DENALI THERAPEUTICS INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12127536

    Humanized M-CSF mice

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12129471

    Materials and methods for treatment of human genetic diseases including hemoglobinopathies

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12129467

    Non-liposomal systems for nucleic acid delivery

    ARBUTUS BIOPHARMA CORPORATION · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12129258

    Diaryl macrocyclic compound and pharmaceutical composition, and use thereof

    PrimeGene (Beijing) Co., Ltd. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12129288

    Polynucleotides heterodimers of soluble interferon receptors and uses thereof

    Sanabio, LLC · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12129307

    HER-2 binding antibodies

    MAB Discovery GmbH · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12128058

    Multi-substituent psilocybin derivatives and methods of using

    Enveric Biosciences Canada Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12128052

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12129469

    Modified short interfering nucleic acid (siNA) molecules and uses thereof

    Aligos Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12129262

    CDK inhibitors and their use as pharmaceuticals

    Prelude Therapeutics, Incorporated · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12128090

    Methods of prophylactic treatment using recombinant VWF (rVWF)

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12129476

    Methods for measuring the potency of AADC viral vectors

    VOYAGER THERAPEUTICS, INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12128013

    Toxic aldehyde related diseases and treatment

    Aldeyra Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12128044

    Fused tricyclic compounds and uses thereof in medicine

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12128033

    Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine

    Neurocrine Biosciences, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12128014

    Use of thiol compounds to treat neurological disease

    MERCAPTOR DISCOVERIES, INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12129222

    Production of bitter principle derivatives

    Julius-Maximilians-Universitaet · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12128036

    Compositions and methods for storage stable ophthalmic drugs

    LENZ THERAPEUTICS OPERATIONS, INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12128048

    Combination therapies using PRMT5 inhibitors for the treatment of cancer

    Mirati Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12128015

    APE/REF1 inhibitors for the treatment of cancer

    The Regents of the University of California · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. WO 2024223388

    COMPLEXES CRISTALLINS ENTRE LA VELAGLIFLOZINE ET DES AGENTS DE FORMATION DE CO-CRISTAUX SÉLECTIONNÉS, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION POUR LA PRÉPARATION DE MÉDICAMENTS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Thu Oct 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12134609

    Quinoline cGAS antagonist compounds

    The Board of Regents of the University of Texas System · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12133831

    Kits for preparing and delivering purified corticotropin

    ANI Pharmaceuticals, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12133890

    Antigen-binding polypeptide targeting B7H3 and application thereof

    NINGBO T-MAXIMUM BIOPHARMACEUTICALS CO., LTD. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12133924

    Compositions and methods for organ specific delivery of nucleic acids

    The Board of Regents of the University of Texas System · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12133853

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12134767

    Materials and methods for treatment of hemoglobinopathies

    Vertex Pharmaceuticals Incorporated · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12134651

    Anti-Ryk antibodies and methods of using the same

    The Regents of the University of California · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12134650

    Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12134648

    Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor

    The Board of Regents of the University of Texas System · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12134642

    Antibodies binding to α7β1 integrin antibodies and compositions thereof

    Pliant Therapeutics, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12133840

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12133884

    Methods of substituting pathogenic amino acids using programmable base editor systems

    Beam Therapeutics Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12133914

    Hydrocortisone oral liquid formulations

    Eton Pharmaceuticals, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12133849

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12133856

    Multi-substituent psilocybin derivatives and methods of using

    Enveric Biosciences Canada Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12134631

    Hydrophilic linkers for antibody drug conjugates

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12134610

    Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2044?

1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.